Triptorelin acetate
As of the edition of 20 October 2026, Triptorelin acetate is a protein: marketed, first approved in 2012 (CA); acts on GNRHR.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2012
- Kind
- Protein
- Brand name
- Decapeptyl
- First approved
- 5 July 2012 (CA)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- Ferring Pharmaceuticals
- Registered trials
- 11, 1 stopped early
- Disease areas
- Urinary and reproductive; Cancer; Pregnancy and women's health; Mental health
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| GNRHR | Gonadotropin-releasing hormone receptor | P30968 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 2 | 2 | 0 | 0 |
| Phase 2 | 3 | 0 | 1 | 0 |
| Phase 3 | 3 | 0 | 2 | 1 |
| Phase 4 | 3 | 0 | 0 | 0 |
| All trials | 11 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Ferring Pharmaceuticals | Applicant | 2012 to now |